I am more than happy for the bulk of the $5m budget for Elixia rollout to be allocated mainly for the Asia/India rollout. With nearly 2 billion people to target, even if it meant our audience was only 200 million of that population, it far outweighs our 20 million.
Bodyshaper is in 500 outlets in Australia. We could see it in the 7000 outlets in SE asia and hopefully through the new distributor in India.
From CCZ equities, quote
A slightly mind blowing thought : with only a partial product rollout it appears that POH is generating circa 130 product sales per week per Myers store. A limited rollout across Watsons’ 2,200 plus store network in Asia, and with sales per store of 40% of what Myers is generating, would imply a potential revenue base out of Asia for Elixia of over $200m in 3 years time!
...and then the US beckons
I'm not saying Oz is not important, but Asia, then the US and europe is where the money is.
POH Price at posting:
18.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)